Moss-FH for patients suffering
from C3 Glomerulopathy (C3G)

Moss-FH is a recombinant protein in development as a treatment for C3 Glomerulopathy (C3G). The structure is identical with human factor H, a regulator of complement activation.

Moss-FH reduces C3 deposition in diseased mice

Moss-FH is a moss-made version of human complement Factor H. As a central regulator of the alternative complement pathway (AP), it is capable of re-establishing complement balance from the dysregulated state of complement diseases such as C3G, aHUS and PNH.

In C3G, the deposition of complement component 3 (C3) in the filtration units of the kidney (glomeruli) leads to substantial damage and ultimately to end stage renal disease. In diseased mice, moss-FH effectively reduces C3-deposition following a single administration, demonstrating the efficacy of moss-FH in balancing the AP.

Treatment with moss-FH has the potential for considerable improvements of patients’ quality of life in life-threatening complement diseases like C3G, aHUS and PNH.

Preclinical trials show treatment with moss-FH reduces C3 deposits in mice kidney

Measurement of C3 deposition in kidney glomeruli in untreated and moss-FH-treated diseased mice, and healthy controls
Measurement of C3 deposition in kidney glomeruli in untreated and moss-FH-treated diseased mice, and healthy controls